Merck, Inc.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- $295.3B
- Website
- http://www.merck.ph
Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)
Phase 2
Terminated
- Conditions
- Metastases, NeoplasmBrain NeoplasmsCarcinoma, Non-Small-Cell Lung
- First Posted Date
- 2002-05-02
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00034697
PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)
Phase 2
Completed
- Conditions
- Mycoses
- First Posted Date
- 2002-05-02
- Last Posted Date
- 2015-12-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 98
- Registration Number
- NCT00034671
A Study in Adult and Pediatric Patients With Cystic Fibrosis
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2002-04-30
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 63
- Registration Number
- NCT00034515
The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients
Phase 4
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 540
- Registration Number
- NCT00002376
- Locations
- ๐บ๐ธ
Kaiser Foundation Hospital, San Francisco, California, United States
Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole
Phase 2
Terminated
- Conditions
- Candidiasis, OralHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 70
- Registration Number
- NCT00005920
- Locations
- ๐บ๐ธ
Carol Sable, Rahway, New Jersey, United States
A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
Phase 2
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6
- Registration Number
- NCT00002235
- Locations
- ๐บ๐ธ
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
๐บ๐ธUniv of Colorado / Health Science Ctr, Denver, Colorado, United States
๐บ๐ธPacific Oaks Med Group, Beverly Hills, California, United States
The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
Not Applicable
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 780
- Registration Number
- NCT00002443
A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis
Not Applicable
Completed
- Conditions
- Candidiasis, EsophagealHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT00005921
- Locations
- ๐บ๐ธ
Gary Calandra, Rahway, New Jersey, United States
Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily
Phase 2
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT00002241
- Locations
- ๐บ๐ธ
Chelsea Village Med Ctr, New York, New York, United States
๐บ๐ธSt Lukes / Roosevelt Hosp / HIV Center, New York, New York, United States
๐บ๐ธUniv of California at San Francisco Gen Hosp, San Francisco, California, United States
The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
Phase 2
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00005118
- Locations
- ๐บ๐ธ
Chicago Ctr for Clinical Research, Chicago, Illinois, United States
๐บ๐ธBisher Akil, Los Angeles, California, United States
๐บ๐ธInstitute of Human Virology, Baltimore, Maryland, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath